2025-522431-34-00招募中2 期
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
Region Hovedstaden4 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2026年10月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,200
- 试验地点
- 4
研究概览
简要总结
To compare the efficacy of molecularly tailored therapy versus standard of care in patients with pancreatic cancer with actionable reimbursed druggable molecular alterations as measured by progression-free survival
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Adult patients (aged 18 and over)
- •Pancreatic cancer confirmed by cytology or histology
- •Written informed consent before any specific study procedures
- •Available personalized report communicating the molecular testing results and detailed treatment options
- •Participants must have received and progressed during or after 1 line of systemic chemotherapy in the advanced setting (gemcitabine or 5-FU based regimens) or within one year of the adjuvant/neoadjuvant treatment
- •ECOG Performance Status 0-2
- •Participants must have normal organ and marrow function as defined below: - Absolute neutrophil count ≥ 1.5 x 10⁹/L - Platelet count ≥ 75 x 10⁹/L - Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) - AST/ALT ≤ 5 x ULN - Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (using the Cockcroft-Gault formula)
- •Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in the protocol
- •Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year
排除标准
- •Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
- •Allergies and Adverse Drug Reaction - History of allergy to study drug components - Hypersensitivity to the active substances
- •WOCBP who are pregnant or breastfeeding
研究组 & 干预措施
OLAPARIB, OLAPARIB
Test
干预措施: OLAPARIB (Drug)
研究者
Sponsor Investigator
Scientific
Region Hovedstaden
研究点 (4)
Loading locations...
相似试验
尚未招募
2 期
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted PsychotherapyNCT07373535Kyle Greenway16
招募中
3 期
TAILORED-PROM: Personalized therapeutic approach for preterm premature rupture of membranes to safely prolong pregnancy, enhance maternal and neonatal outcomes, and minimize unnecessary antibiotic use.2024-520237-77-00Vseobecna Fakultni Nemocnice V Praze138
已完成
不适用
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology SettingNCT07374120Novartis Pharmaceuticals1,480
招募中
2 期
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX)2024-510645-34-00Unicancer225
尚未招募
2 期
A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALLLALNCT07522801Philippe ROUSSELOT93